In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease.
From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...
A federal judge has ordered the Trump administration to reinstate content that was recently removed from the Centers for ...
Federal health agencies have restored several webpages and datasets, following a judge's order to bring back public access to information that had been removed to comply with a presidential executive ...
Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and ...
Information has mysteriously disappeared from the U.S. government's health websites. Here's what we know, and where to find ...
The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...